Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug579 | Biomarkers expression Wiki | 0.58 |
| drug1961 | Interferon alfa Wiki | 0.58 |
| drug3566 | Selinexor Wiki | 0.33 |
Navigate: Correlations HPO
There are 3 clinical trials
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and reduce the time to recovery in hospitalized subjects with severe or critical COVID-19 pneumonia.
Description: Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized, not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities).
Measure: Time to Recovery Time: Up to 28 daysDescription: Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Measure: Percentage of Participants Experiencing Adverse Events Time: Up to 60 daysDescription: Using the NCI CTCAE version 5.0
Measure: Percentage of Participants Experiencing Serious Adverse Events Time: Up to 60 daysDescription: NEWS2 consists of: Physiological Parameters: respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), use of air or oxygen, systolic blood pressure (mmHg), pulse (per minute), consciousness and temperature (°C)
Measure: Time to Clinical Improvement, Defined as NEWS2 < 2 Maintained for 24 Hours Time: Up to Day 28A multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population. ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts. ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus. ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection. ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection. Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection. It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population.
Description: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)
Measure: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab) Time: 3 months from baseline.Description: incidence of any upper or lower community acquired respiratory viral infection (define as identification of respiratory viruses such as coronavirus other than SARS-CoV-2, influenza, parainfluenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus). assessed using local standard of care testing (e.g. respiratory swabs, saliva and/or blood)
Measure: incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing Time: 3 months from baseline.Description: incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .
Measure: incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab . Time: 28 days from baselineDescription: incidence of any upper or lower community acquired respiratory viral infection (define as identification of respiratory viruses such as coronavirus other than SARS-CoV-2, influenza, parainfluenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus). Assessed using local standard of care testing (e.g. respiratory swabs, saliva and/or blood)
Measure: incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing Time: 28 days from baselineDescription: composite outcome: incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records
Measure: incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records Time: 60 days from baselineDescription: time to clinical improvement (defined as a two point reduction in clinical progress ordinal scale) or discharge from hospital, whichever occurs first. assessed using medical records
Measure: time to clinical improvement or discharge from hospital assessed using medical records Time: 28 days from baselineDescription: ARM 1, secondary endpoint 1 Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. (composite either COVID-19 or other respiratory viral infection). assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.
Measure: ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool Time: 120 days from baselineDescription: ARM 1, secondary endpoint 2 Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records
Measure: ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 3. Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records
Measure: ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 4 Illness severity in case of confirmed COVID-19 diagnosed during the study period, defined as the maximal score on the World Health Organization (WHO)'s clinical progression scale ranging from 0 (uninfected) to 10 (death)
Measure: ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale Time: 120 days from baselineDescription: ARM 1, secondary endpoint 5 Incidence of unplanned all-cause hospital admission during the study period. Composite measure: duration of hospital stay if outcome met. assessed using medical records
Measure: ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 6 Incidence of unplanned infection-related hospital admission during the study period. Composite measure: duration of hospital stay if outcome met. assessed using medical records
Measure: ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 7 Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR
Measure: ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR Time: 120 days from baselineDescription: ARM 1, secondary endpoint 8 Incidence of death from any cause during the study period. assessed using patient medical records
Measure: ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 9 Incidence of testing for COVID-19 during the study period. Composite measure: frequency of testing if outcome is met. assessed using medical records
Measure: ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records Time: 120 days from baselineDescription: ARM 2: secondary outcome 1. Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period (days). assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.
Measure: ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records. Time: 28 days from baselineDescription: ARM 2: secondary outcome 2. Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records
Measure: ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records Time: 28 days from baselineDescription: ARM 2: secondary outcome 3. Illness severity in case of confirmed COVID-19 diagnosed during the study period, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death)
Measure: ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale. Time: 28 days from baselineDescription: ARM 2: secondary outcome 4. Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.
Measure: ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records. Time: 28 days from baselineDescription: ARM 2: secondary outcome 5 Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records
Measure: ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records Time: 28 days from baselineDescription: ARM 2: secondary outcome 6 Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.
Measure: ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR. Time: 28 days from baselineDescription: ARM 2: secondary outcome 7. Incidence of testing for COVID-19 during the study period. Composite measure: frequency of testing if outcome is met. assessed using medical records
Measure: ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records Time: 28 days from baselineDescription: ARM 3: secondary outcome 1 Time to clinical improvement defined as Resolution of fever - oral temperature < 38oC for 24 hours without antipyretics AND Respiratory rate < 20 breaths/minute OR Oxygen saturation > 94% on room air OR Hospital discharge assessed using medical records
Measure: ARM 3: Time to clinical improvement assessed using medical records. Time: 60 days from baselineDescription: ARM 3: secondary outcome 2. Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death)
Measure: ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale Time: 60 days from baselineDescription: ARM 3: secondary outcome 3 change to clinical condition assessed with Karnofsky Performance score
Measure: ARM 3: change to clinical condition assessed with Karnofsky Performance score Time: 60 days from baselineDescription: ARM 3: secondary outcome 4. Time to progression to severe COVID-19, defined by WHO ordinal scale
Measure: ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale Time: 60 days from baselineDescription: ARM 3: secondary outcome 5 Time to all-cause mortality
Measure: ARM 3: Time to all-cause mortality Time: 60 days from baselineDescription: ARM 3: secondary outcome 6. Duration of hospitalisation. assessed using medical records
Measure: ARM 3:Duration of hospitalisation assessed using medical records Time: at discharge or day 60 whichever is soonerDescription: ARM 3: secondary outcome 7 Duration of COVID-19 symptoms assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.
Measure: ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary. Time: 60 days from baselineDescription: ARM 3: secondary outcome 8. Duration of oxygen supplementation (days). assessed using medical records.
Measure: ARM 3: Duration of oxygen supplementation (days). assessed using medical records. Time: 60 days from baselineDescription: ARM 3: secondary outcome 9 change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)
Measure: ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR) Time: 60 days from baselineDescription: ARM 3: secondary outcome 10. Safety and tolerability of selinexor defined as listing and documentation of frequency and severity of adverse effects. Outcome assessed using any/all of medical records, patient reported, vital signs, ECG, imaging, other investigative procedure as per standard local practice.
Measure: ARM 3: Safety and tolerability of selinexor using relevant medical records Time: 60 days from baselineDescription: ARM 3: secondary outcome 11. composite outcome: incidence of changes in blood results relevant to clinical improvement. Changes in C-reactive protein (CRP) Changes in ferritin level Changes in lactate dehydrogenase (LDH) level
Measure: ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records Time: 60 days from baselineDescription: ARM 4: secondary outcome 1 Incidence of all cause death by day 28 and 60 assessed using medical records
Measure: ARM 4: Incidence of all cause death by day 28 and 60 Time: day 28 from baseline and day 60 from baselineDescription: ARM 4: secondary outcome 2 Time to all-cause mortality assessed using medical records
Measure: ARM 4: Time to all-cause mortality Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 3 - composite outcome: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death) Proportion who have recovered (defined as 0-4) Proportion who had 1 point improvement Proportion who had 2 point improvement
Measure: ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 4 Incidence of ARDS. assessed using medical records
Measure: ARM 4: Incidence of ARDS assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 5 incidence of HLH. assessed using medical records
Measure: ARM 4: incidence of HLH. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 6 Duration of hospitalisation. assessed using hospital medical records.
Measure: ARM 4: Duration of hospitalisation. assessed using hospital medical records. Time: at discharge or by day 60 whichever is soonerDescription: ARM 4: secondary outcome 7 Proportion discharged from hospital. assessed using medical records
Measure: ARM 4: Proportion discharged from hospital. assessed using medical records Time: at dischargeDescription: ARM 4: secondary outcome 8. Incidence of mechanical ventilation up to day 28. assessed using medical records
Measure: ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records Time: any time up day 28 from baselineDescription: ARM 4: secondary outcome 9 composite outcome: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records
Measure: ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 10. composite outcome: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.
Measure: ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records. Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 11 composite outcome: Incidence and duration of ICU admission. assessed using medical records
Measure: ARM 4: Incidence and duration of ICU admission. assessed using medical records Time: at discharge or by day 60 from baseline.Description: ARM 4: secondary outcome 12 composite outcome: incidence and duration of supplemental oxygen use. assessed using medical records
Measure: ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 13. Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours. assessed using medical records
Measure: ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours. Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 14 incidence of non-invasive ventilation. assessed using medical records
Measure: ARM 4: incidence of non-invasive ventilation. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 15. composite outcome: number of participants alive and off oxygen at day 60. assessed using medical records.
Measure: ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records. Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 16 proportion of participants who had improved oxygenation for >48 hours. assessed using medical records
Measure: ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records Time: any time up to 28 days from baselineDescription: ARM 4: secondary outcome 17 Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records
Measure: ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records Time: any time up to day 28 from baseline.Description: ARM 4: secondary outcome 18 incidence of SAEs based on NCI CTCAE v5 assessed using medical records
Measure: ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records Time: any time up to 28 days from baseline.Description: ARM 4: secondary outcome 19 change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.
Measure: ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR. Time: any time up to day 60 from baselineThis is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with COVID-19. BET is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 40 sites throughout the US. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention. The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses. One or more interventions may be started at any time. The number of interventions enrolling are programmatic decisions and will be based on the number of sites and the pace of enrollment. At the time of enrollment, subjects will be randomized to receive any one of the active arms they are eligible for or placebo. Approximately 100 subjects will be assigned to each arm entering the platform and a given site will generally have no more than 3 interventions at once. The BET-B stage will evaluate the combination of remdesivir with lenzilumab vs remdesivir with a lenzilumab placebo. The primary objective is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.
Description: Clinical status assessed using ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Measure: Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale Time: Day 8Description: The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure.
Measure: Change in National Early Warning Score (NEWS) from baseline Time: Day 1 through Day 29Description: Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care.
Measure: Clinical efficacy, as assessed by time to recovery Time: Day 1 through Day 29Description: For any reason.
Measure: Discontinuation or temporary suspension of study product administration Time: Day 1 through Day 29Description: Measured in days.
Measure: Duration of hospitalization Time: Day 1 through Day 29Description: Measured in days.
Measure: Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use Time: Day 1 through Day 29Description: Measured in days.
Measure: Duration of new non-invasive ventilation or high flow oxygen use during the study Time: Day 1 through Day 29Description: Measured in days; supplemental oxygen concentration or flow rate will be measured.
Measure: Duration of new oxygen use Time: Day 1 through Day 29Description: Measured in days.
Measure: Duration of non-invasive ventilation/high flow oxygen use Time: Day 1 through Day 29Description: Supplemental oxygen concentration or flow rate will be measured.
Measure: Incidence of new oxygen use Time: Day 1 through Day 29Description: Measured in days.
Measure: Incidence of ventilator/ extracorporeal membrane oxygenation (ECMO) use Time: Day 1 through Day 29Description: Clinical outcome assessed using ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Measure: Mean change in the ordinal scale Time: Day 1 through Day 29Description: Measured in days; supplemental oxygen concentration or flow rate will be measured.
Measure: Oxygenation use Time: Day 1 through Day 29Description: A subject who is "alive and without respiratory failure" is defined as meeting any one of the following five categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3)Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen.
Measure: Proportion of subjects alive and without respiratory failure Time: Day 1 through Day 29Description: Date and cause of death (if applicable).
Measure: Subject 14-day mortality Time: Day 1 through Day 15Description: Date and cause of death (if applicable).
Measure: Subject 29-day mortality Time: Day 1 through Day 29Description: Clinical outcome assessed using ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Measure: Time to an improvement of one category using an ordinal scale Time: Day 1 through Day 29Description: Clinical outcome assessed using ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Measure: Time to an improvement of two categories using an ordinal scale Time: Day 1 through Day 29Description: The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure.
Measure: Time to discharge or to a National Early Warning Score (NEWS) of < / = 2 and maintained for 24 hours, whichever occurs first Time: Day 1 through Day 29Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports